Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R.

J Infect Dis. 2012 Jan 1;205(1):82-6. doi: 10.1093/infdis/jir708. Epub 2011 Nov 7.

2.

Human T-cell leukemia virus type 2 antisense viral protein 2 is dispensable for in vitro immortalization but functions to repress early virus replication in vivo.

Yin H, Kannian P, Dissinger N, Haines R, Niewiesk S, Green PL.

J Virol. 2012 Aug;86(16):8412-21. doi: 10.1128/JVI.00717-12. Epub 2012 May 23.

3.

Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers.

Mori S, Mizoguchi A, Kawabata M, Fukunaga H, Usuku K, Maruyama I, Osame M.

Thorax. 2005 Feb;60(2):138-43.

4.

Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP).

Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, Takenouchi N, Izumo S, Osame M, Jacobson S.

Blood. 2002 Jan 1;99(1):88-94.

5.

Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.

Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard JM, Barbeau B, Mahieux R.

Blood. 2009 Sep 17;114(12):2427-38. doi: 10.1182/blood-2008-09-179879. Epub 2009 Jul 14.

6.

Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion.

Kannian P, Yin H, Doueiri R, Lairmore MD, Fernandez S, Green PL.

J Virol. 2012 Apr;86(7):3757-66. doi: 10.1128/JVI.06900-11. Epub 2012 Jan 25.

7.

Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry.

Lee TH, Chafets DM, Busch MP, Murphy EL.

J Clin Virol. 2004 Dec;31(4):275-82.

PMID:
15494269
8.

[HTLV-1 and HTLV-2 proviral load: a simple method using quantitative real-time PCR].

Tamegão-Lopes BP, Rezende PR, Maradei-Pereira LM, de Lemos JA.

Rev Soc Bras Med Trop. 2006 Nov-Dec;39(6):548-52. Portuguese.

9.

Quantification of HTLV-II proviral copies by competitive polymerase chain reaction in peripheral blood mononuclear cells of Italian injecting drug users, central Africans, and Amerindians.

Cimarelli A, Duclos CA, Gessain A, Cattaneo E, Casoli C, Biglione M, Mauclère P, Bertazzoni U.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):198-204.

PMID:
7552486
10.

Human T-cell lymphotropic virus type 3 (HTLV-3)- and HTLV-4-derived antisense transcripts encode proteins with similar Tax-inhibiting functions but distinct subcellular localization.

Larocque É, Halin M, Landry S, Marriott SJ, Switzer WM, Barbeau B.

J Virol. 2011 Dec;85(23):12673-85. doi: 10.1128/JVI.05296-11. Epub 2011 Sep 14.

11.

Investigation of proviral load in individuals infected with human T-lymphotropic virus type II.

Woods TC, Graber JM, Hershow RC, Khabbaz RF, Kaplan JE, Heneine W.

AIDS Res Hum Retroviruses. 1995 Oct;11(10):1235-9.

PMID:
8573380
12.

Low DNA HTLV-2 proviral load among women in São Paulo City.

Montanheiro P, Olah I, Fukumori LM, Smid J, Oliveira AC, Kanzaki LI, Fonseca LA, Duarte AJ, Casseb J.

Virus Res. 2008 Jul;135(1):22-5. doi: 10.1016/j.virusres.2008.01.015. Epub 2008 Mar 17.

PMID:
18343520
13.

Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.

Beilke MA, Traina-Dorge VL, Sirois M, Bhuiyan A, Murphy EL, Walls JM, Fagan R, Winsor EL, Kissinger PJ.

Clin Infect Dis. 2007 May 1;44(9):1229-34. Epub 2007 Mar 19.

14.

Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load.

de Souza JG, da Fonseca FG, Martins ML, Martins CP, de Carvalho LD, Coelho-dos-Reis JG, Carneiro-Proietti AB, Martins-Filho OA, Barbosa-Stancioli EF; GIPH.

J Clin Virol. 2011 Jan;50(1):13-8. doi: 10.1016/j.jcv.2010.09.007. Epub 2010 Oct 15.

PMID:
20951636
15.

Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers.

Akimoto M, Kozako T, Sawada T, Matsushita K, Ozaki A, Hamada H, Kawada H, Yoshimitsu M, Tokunaga M, Haraguchi K, Uozumi K, Arima N, Tei C.

J Med Virol. 2007 Jul;79(7):977-86.

PMID:
17516523
16.

Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo.

Yamamoto B, Li M, Kesic M, Younis I, Lairmore MD, Green PL.

Retrovirology. 2008 May 12;5:38. doi: 10.1186/1742-4690-5-38.

17.

In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs.

Machuca A, Soriano V.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):189-93.

PMID:
10935697
18.

Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells.

Usui T, Yanagihara K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y, Kamihira S.

Retrovirology. 2008 Apr 22;5:34. doi: 10.1186/1742-4690-5-34.

19.

Correlation between LTR point mutations and proviral load levels among human T cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers.

Neto WK, Da-Costa AC, de Oliveira AC, Martinez VP, Nukui Y, Sabino EC, Sanabani SS.

Virol J. 2011 Dec 13;8:535. doi: 10.1186/1743-422X-8-535.

20.

Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data.

Kwaan N, Lee TH, Chafets DM, Nass C, Newman B, Smith J, Garratty G, Murphy EL; HTLV Outcomes Study (HOST) Investigators.

J Infect Dis. 2006 Dec 1;194(11):1557-64. Epub 2006 Oct 27.

Items per page

Supplemental Content

Write to the Help Desk